Clinical evaluation of blood glucose variability with continuous intravenous measurement in ICU patients (GLIC-study)

Completed

• Conditions: hyperglycemia; stress diabetes; 10018424

• Registration Number: NL-OMON40555
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Age of 18 years or older, surgical or medical patients admitted to the ICU or MCU with a planned stay at the ICU of at least 8 hours.

Exclusion Criteria

No informed consent
Contra-indication or allergy for heparin
Glucose in targetrange (4.4-6.1 mmol/L)
Pregnancy
Difficult to place a peripheral intravenous catheter

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint in this study is to evaluate the added value of continuous<br /><br>intravenous measurement of blood glucose variability after cardiothoracic<br /><br>surgery and during treatment at respectively, the Intensive Care Unit and<br /><br>Medium Care Unit.<br /><br><br /><br>Study parameters in this study are calculation of:<br /><br>- mean glucose (mmol/L) (per patient, per subgroup, total average)<br /><br>- percentage of patients observed experiencing severe hyperglycemia (glucose ><br /><br>10.0 mmol/L),<br /><br>- percentage of mild hyperglycemia (glucose 6.1-10.0 mmol/L)<br /><br>- percentage of mild hypoglycaemia (2.2-3.9 mmol/L)<br /><br>- percentage of severe hypoglycaemia (<2.2 mmol/L)<br /><br>- percentage of time out of target range (4.4 * 6.1 mmol/L)<br /><br>- percentage of blood glucose CV (coefficient of variation) (in %). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p> -</p><br>